

Metabolic alkalosis and mortality in COVID-19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Dr Zhifeng Jiang (Correspondence author) ,Xiaogan Hospital Affiliated to Wuhan University of Science and Technology; No.6, Square street, Xiaonan District, Xiaogan City, Hubei Province, China. email addresses : xjiang292@sina.com.

25 **Abstract**

26 **Background**

27 As a new infectious disease affecting the world, COVID-19 has caused a huge impact
28 on countries around the world. At present, its specific pathophysiological mechanism
29 has not been fully clarified. We found in the analysis of the arterial blood gas data of
30 critically ill patients that the incidence of metabolic alkalosis in such patients is high.

31 **Method**

32 We retrospectively analyzed the arterial blood gas analysis results of a total of 16
33 critically ill patients in the intensive ICU area of Xiaogan Central Hospital and 42
34 severe patients in the intensive isolation ward, and analyzed metabolic acidosis and
35 respiratory acidosis. Metabolic alkalosis and respiratory alkalosis, and the relationship
36 between metabolic alkalosis and death.

37 **Result**

38 Among the 16 critically ill patients, the incidence of metabolic alkalosis was 100%,
39 while the incidence of metabolic alkalosis in severe patients was 50%; the mortality
40 rate in critically ill patients was 81.3%, and 21.4% in severe patients ; The mortality
41 of all patients with metabolic alkalosis is 95.5%,and 4.5% in without metabolic
42 alkalosis.

43 **Conclusion**

44 The incidence of metabolic alkalosis in critically ill COVID-19 patients is high, and it
45 is associated with high mortality.

46 **Key words** :COVID-19, Metabolic alkalosis, mortality

47 **Introduction**

48 COVID-19 has now swept the world, causing huge challenges and disasters to the
49 global health system. At present, its detailed pathophysiological mechanism has not
50 yet been fully clarified. The current research involves direct virus attack, humoral and
51 cellular immunity, and nervous system damage. Endocrine disorders, respiratory and
52 circulatory disorders, coagulation dysfunction and other aspects(1). There is still a
53 lack of effective treatments. Critically ill patients still have a high mortality rate. Early
54 data from Wuhan showed that the mortality rate of severely ill patients with
55 COVID-19 was 62%, and the mortality rate of patients requiring mechanical
56 ventilation was 81%(2). This manuscript analyzes the blood gas analysis data and
57 deaths of critically ill patients in Xiaogan Central Hospital in March 2020, and finds
58 that the incidence of metabolic alkalosis in critically ill patients is very high, and it is
59 accompanied by a higher mortality rate.

60 **Method**

61 Follow the Helsinki Declaration as revised in 2013, we analyzed 44 patients in the
62 intensive isolation ward of Xiaogan Central Hospital, with an average age of 53 years,
63 27 males and 15 females. There was no history of Gitelman and Bartter syndrome in
64 all patients, and exclude 2 cases of primary aldosteronism in patients. According to
65 the diagnostic criteria of the fifth edition of China's new coronavirus diagnosis and
66 treatment guidelines (meet any of the following 1. Respiratory distress, RR>30
67 beats/min; 2. In the resting state, the oxygen saturation is <93%; 3. Arterial partial
68 pressure of oxygen (PaO₂)/inhaled oxygen concentration (FiO₂) <300mmHg). All 42

69 patients were diagnosed as severe. Analyzing the arterial blood gas analysis data and
70 death data of 42 patients; According to the same diagnostic criteria, we analyzed the
71 arterial blood gas analysis data and death data of a total of 16 critically ill patients, 11
72 were males and 5 were females, with an average age of 67 years. (meet one of the
73 following conditions:1. Respiratory failure occurs and mechanical ventilation is
74 required; 2.Shock;3. combined with other organ failure, ICU monitoring and
75 treatment is required) in the intensive ICU of our hospital.

76 Analyze the arterial blood gas data of all patients, select the highest bicarbonate value
77 as the statistical data, including carbon dioxide partial pressure (PaCO₂), oxygen
78 partial pressure (PaO₂), bicarbonate (HCO₃⁻), alkali excess (BE), serum potassium
79 and calculate acid-base imbalance types, including metabolic acidosis, respiratory
80 acidosis, metabolic alkalosis, respiratory alkalosis, respiratory acidosis combined with
81 metabolic alkalosis, and analyze the mortality of critical and severe patients, at the
82 same time, compare the mortality of patients with metabolic alkalosis and
83 non-metabolic alkalosis. In addition, respiratory acidosis combined with metabolic
84 alkalosis and metabolic alkalosis were combined as metabolic alkalosis, and the
85 incidence of alkalosis and mortality were compared again ,simultaneously compare
86 the serum potassium of the two groups of patients. Use spss25.0 statistical software to
87 analyze this data. The basic description of the count data is expressed by frequency
88 and composition ratio, and the analysis of the difference between the two groups of
89 count data uses the χ^2 test, t test is used for measurement data, P<0.05 indicates that
90 the difference is statistically significant.

91 **Result**

92 There were 10 cases of acid-respiratory and metabolic alkalosis in critically ill
93 patients, with an incidence rate of 62.5%, and 11 cases of acid-respiratory and
94 metabolic alkalosis in severe patients, with an incidence of 26.2%, χ^2 was 6.613,
95 $P=0.010$, there was a statistical difference in the incidence of the two groups. The
96 incidence of acid and alkali substitution in critical cases was significantly higher than
97 that in severe cases. There were 6 cases of metabolic alkalosis alone in critically ill
98 patients with an incidence rate of 37.5%, and 10 cases of metabolic alkalosis in severe
99 patients with an incidence rate of 23.8%, χ^2 was 1.087, $P=0.297$, there was no
100 statistical difference in the occurrence of metabolic alkalosis between the two groups.
101 However, when the number of cases of respiratory acidosis combined with metabolic
102 alkalosis and metabolic alkalosis are combined, the incidence of metabolic alkalosis
103 in critical cases is 100%, and the incidence of metabolic alkalosis in severe patients is
104 50%.(Table 1)

105 Comparing the two groups of patients with simple metabolic alkalosis and respiratory
106 acidosis combined with metabolic alkalosis, it was found that among the dead patients,
107 14 cases of respiratory acidosis combined with metabolic alkalosis accounted for
108 63.6%, there are no respiratory acidosis combined with metabolic alkalosis in 8 case,
109 accounting for 3.4%, with a χ^2 of 11.546 and a P value of 0.001; When analyzing the
110 death of patients with simple metabolic alkalosis, it was found that the death had
111 nothing to do with simple metabolic alkalosis, χ^2 was 0.318, $P=0.573$,when
112 respiratory acidosis combined with metabolic alkalosis and metabolic alkalosis are

113 combined as the number of cases of metabolic alkalosis, a total of 21 deaths, a ratio of
114 95.5%, and no metabolic alkalosis is 1 death, accounting for 4.5%, the χ^2 was
115 15.383, and the P value is 0.000, the incidence of metabolic alkalosis is higher in
116 deceased patients; Serum potassium in the critically ill was 3.41+-0.4mmol/L, and
117 3.68±0.46mmol/l in severe group, critically ill patients have lower blood potassium
118 than severe patients (Table2).

119 **Discusstion**

120 COVID-19 patients experience a variety of acid-base balance disorders during their
121 course of disease. The assessment and research on the acid-base balance disorders of
122 COVID-19 patients is still insufficient (3), which is different from our conventional
123 understanding-the main target of damage due to COVID-19 The organ is the lung,
124 which may cause respiratory acid-base balance disorders. A retrospective blood gas
125 analysis study showed that the most common acid-base balance disorder in patients
126 with COVID-19 is keratogenic alkalosis(3). A report from South Africa has been
127 shown that metabolic alkalosis is more common in COVID-19 virus-positive patients
128 (4). Our research also shows that metabolic alkalosis is the most common acid-base
129 balance disorder in such patients.

130 The causes of metabolic alkalosis include extrarenal factors and renal factors.
131 extrarenal factors include gastric acid loss, such as vomiting, nasogastric tube
132 drainage, and loss of intestinal acid, such as villous adenoma, congenital celiac
133 disease, excessive oral or parenteral intake of bicarbonate; Kidney factors such as
134 high mineralocorticoid activity and high distal sodium delivery, persistent

135 mineralocorticoid overdose, potassium deficiency(5).Our severe patients do not have
136 the above-mentioned extrarenal factors, unintentional excessive intake of bicarbonate,
137 and a small number of critically ill patients have nasogastric tube drainage, so such a
138 high incidence of metabolic alkalosis needs to consider renal factors.

139 The destruction of cells entering the viral receptor, angiotensin-converting enzyme
140 (ACE-2) II, is considered to be one of the main causes of human pathogenicity of
141 SARS-CoV-2. ACE-2 is widely expressed in renal tubular epithelial cells, vascular
142 components and glomerular epithelium (6). Once the SARS-CoV-2 bound ACE-2 is
143 internalised by the cell, ACE2 is markedly downregulated (7) . Theoretically, it
144 should lead to the excessive renin-angiotensin-aldosterone system mediated by excess
145 angiotensin II activate (8, 9).

146 In addition, studies have reported widespread hypokalemia in COVID-19 patients.

147 The publication of a preprinted retrospective chinese study initially sparked interest in
148 hypokalemia, which is a potentially common biochemical disorder in SARS-CoV-2
149 infection, and serum potassium was present in 108 of 175 patients <3.5 mmol/l (62%),
150 only 10 patients had serum K> 4.0 mmol/l. Of these patients, 22% had severe
151 hypokalemia (serum potassium <3.0 mmol/l). In total, 11% of all patients and 28% of
152 patients with severe hypokalemia showed metabolic alkalosis (pH> 7.45), compared
153 with 4% of patients with normal potassium. (10) However, the largest SARS-CoV-2
154 case series to date (including 1,099 patients) did not show any significant difference
155 in serum potassium between mild and severe patients, in this cohort, serum potassium
156 was mostly reported as normal (11).Our research shows that there is no significant

157 difference in serum potassium between critically ill and critically ill patients, but both
158 are at a low level.

159 Virtually all forms of metabolic alkalosis are sustained by enhanced collecting duct
160 hydrogen ion secretion, induced by stimulation of sodium uptake through the
161 epithelial sodium channel(12). In the renal collecting duct, mineralocorticoids drive
162 Na^+ reabsorption, K^+ secretion, and H^+ secretion through coordinated actions on
163 apical and basolateral transporters(13).

164 Therefore, we speculate that SARS-CoV-2 uses ACE-2 as its cell receptor, leading to
165 ACE2 degradation and ACE/ACE-2 imbalance, increasing Ang II levels, inducing the
166 release of aldosterone and increasing mineralocorticoids, which in turn leads to
167 blood potassium reduction and metabolic alkalosis. In addition, patients with
168 COVID-19 often have small airway ventilatory disorders, complicated by respiratory
169 acid. In patients with acute respiratory acidosis, PaCO_2 increases by 10 mmHg,
170 HCO_3^- increases by 1 mmol/l, while in chronic respiratory acidosis patients, PaCO_2
171 increases by 1 mmol/l. In patients with acidosis, for every 10 mmHg increase in
172 PaCO_2 , HCO_3^- increases by 4 mmol/l. In the post-hypercapnia state, respiratory
173 acidosis improves (such as receiving mechanical ventilation), but HCO_3^- continues
174 to rise, leading to metabolic alkalosis(14). In addition, in this study, the patient intake
175 data cannot be counted in detail. Whether there is insufficient intake and aggravation
176 of alkalosis needs further evaluation.

177 Metabolic alkalosis can lead to a series of serious consequences. First, elevated pH
178 leads to respiratory depression, and alkalosis is a powerful vasoconstrictor. A large

179 number of studies have shown that increase in pH leads to a decrease in perfusion of
180 the heart, brain and peripheral circulation(15).

181 Metabolic alkalosis is the most common acid-base disorder in hospitalized patients,
182 and it is associated with increased mortality. An earlier study by Wilson et al. in 1415
183 critically ill surgical patients showed that 177 (12%) developed severe metabolic
184 alkalosis defined as arterial pH >7.54 (15). More severe metabolic alkalosis was
185 associated with higher mortality. Mortality was 41% in patients with pH 7.55-7.56, 47%
186 in patients with pH 7.57-7.59, 65% in patients with pH 7.60-7.64, and 80% in patients
187 with pH 7.65-7.70. A prospective study by Anderson et al. in a group of 409 medical
188 and surgical patients showed that mortality was 48.5% in patients with pH >7.60 (16).
189 This study shows that among critically ill patients, the incidence of metabolic
190 alkalosis is 100% and the mortality rate is 81.25%, and the mortality rate of severe
191 and critically ill patients with metabolic alkalosis is as high as 95.5%.

192 However, the amount of data in this study is still small, and there may be therapeutic
193 factors that interfere with the acid-base balance during the treatment of patients.If a
194 large sample, a more detailed stratified design, and dynamic detection of patient
195 ACE-2/renin-angiotensin-aldosterone levels can reveal more secrets.

196 In conclusion, in severe and critically ill patients, the proportion of metabolic
197 alkalosis has increased significantly, and the mortality rate in patients with metabolic
198 alkalosis has increased significantly. In COVID-19 patients, we need to pay attention
199 to kidney damage as much as the lungs.

200

201 **Declarations**

202 **Conflicts of interest:** The authors declare that they have no competing interests.

203 **Funding:** There are no funding.

204 **Consent statement:** Written consent was obtained from the patient/ guardian.

205 **Acknowledgments:** We Thank Dr.Aiqiao Feng, Dr. Zhibin Xie,Dr Tao Li, Dr.Sai

206 Xie,and Dr. Xiaofei Hu for contributions to the diagnosis and treatment of patients

207 and writing suggestions.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235 **Reference**

- 236 1 Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological
237 findings in COVID-19: a pathophysiological timeline and possible mechanisms
238 of disease progression. *Mod Pathol.* 2020 Jun 22 : 1–11.
- 239 2 Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with
240 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
241 observational study. *Lancet Respir Med.* 2020.
- 242 3 Alfano G, Fontana F, Mori G, et al. Acid base disorders in patients
243 with COVID-19. *Int Urol Nephrol.* 2021 Jun 11 : 1–6.
- 244 4 J Rood, R Davids, A Le Roux, et al. A Parker, B W Allwood, H W Prozesky, C
245 F N Koegelenberg, J J Taljaard. Metabolic alkalosis in hospitalised COVID-19
246 patients: A window to the pathogenesis? *S Afr Med J.* 2020 Oct
247 1;110(11):13109.
- 248 5 Palmer BF, Alpern RJ. Metabolic Alkalosis. *J Am Soc Nephrol.*
249 1997 ;Sep;8(9):1462-9.
- 250 6 Owen Wiese, Annalise E, Zemlin , et al. Molecules in pathogenesis: angiotensin
251 converting enzyme 2 (ACE2). *J Clin Pathol.* 2020 Aug : jclinpath-2020-206954.
- 252 7 Morag J Young, Colin D Clyne, Karen E Chapman. Endocrine aspects of ACE2
253 regulation: RAAS, steroid hormones and SARS-CoV-2. *J Endocrinol.* 2020
254 Nov;247(2):R45-R62.
- 255 8 Alfano G, Guaraldi G, Fontana F, et al. The role of the renin-angiotensin system
256 in severe acute respiratory syndrome-CoV-2 infection. *Blood Purif.*
257 2021;50(2):263-267.

- 258 9 Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2)
259 in COVID-19. *Crit Care*. 2020;24:422.
- 260 10 Dong Chen, Xiaokun Li, Qifa Song, et al. Assessment of Hypokalemia and
261 Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou,
262 China *JAMA Netw Open*. 2020 Jun; 3(6): e2011122.
- 263 11 Guan WJ, Ni ZY, Hu Y, et al. : Clinical Characteristics of Coronavirus Disease
264 2019 in China. *N Engl J Med*. 2020;382:1708–1720.
- 265 12 F John Gennari. Pathophysiology of metabolic alkalosis: a new classification
266 based on the centrality of stimulated collecting duct ion transport. *Am J Kidney*
267 *Dis*. 2011 Oct;58(4):626-36.
- 268 13 Megan M Greenlee, I Jeanette Lynch, Michelle L Gumz, et al. Mineralocorticoids
269 Stimulate the Activity and Expression of Renal H⁺,K⁺-ATPases. *J Am Soc*
270 *Nephrol*. 2011 Jan; 22(1): 49–58.
- 271 14 Banga A, Khilnani GC. Post-hypercapnic alkalosis is associated with ventilator
272 dependence and increased ICU stay. *COPD J Chronic Obstr Pulm*
273 *Dis*. 2009;6:437–440.
- 274 15 Wilson RF, Gibson D, Percinel A, et al. Severe alkalosis in critically ill surgical
275 patients. *Arch Surg*. 1972;105:193–203.
- 276 16 Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in
277 medical and surgical patients. *South Med J*. 1987; 80:729–733.

278

279

group	case	critically ill	Severe	χ^2/t	P
AC &MA				6.613	0.010
Yes	21	10(62.5%)	11(26.2%)		
No	37	6(37.5%)	31(73.8%)		
Metabolic alkalosis				1.087	0.297
Yes	16	6(37.5%)	10(23.8%)		
No	42	10(62.5%)	32(76.2%)		
Death				17.611	0.000
Yes	22	13(81.3%)	9(21.4%)		
No	36	3(18.8%)	33(78.6%)		
Combined metabolic alkalosis				12.541	0.000
Yes	21	16(100.0%)	21(50.0%)		
No	21	0(0.0%)	21(50.0%)		
Serum potassium	-	3.41 ± 0.40	3.68 ± 0.46	-2.026	0.048

280 Table1 Comparison of the incidence of acid-base balance disorders in critically ill
 281 and critically ill patients.(AC &MA: Respiratory acidosis combined with metabolic
 282 alkalosis)

283

284

285

286

287

288

289

290

291

292

293

group	case	no death	death	χ^2	P
AC &MA				11.546	0.001
Yes	21	7(19.4%)	14(63.6%)		
No	37	29(80.6%)	8(36.4%)		
metabolic alkalosis				0.318	0.573
Yes	16	9(25.0%)	7(31.8%)		
No	42	27(75.0%)	15(68.2%)		
Combined metabolic alkalosis				15.383	0.000
Yes	37	16(44.4%)	21(95.5%)		
No	21	20(55.6%)	1(4.5%)		

294 Table 2 Number of deaths in acid-base imbalance.(AC &MA: Respiratory
 295 acidosis combined with metabolic alkalosis)

296